{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:46:42Z","timestamp":1792201602258,"version":"4.4.0"},"reference-count":53,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":323,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Centre for Evaluation and Health Technology Assessment"},{"name":"Diabetes Fund of the National Board of Health"},{"DOI":"10.13039\/100008392","name":"Danish Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002739","name":"Aarhus University Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002739","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Foundation for the Study of Diabetes\/Pfizer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes","award":["74550801"],"award-info":[{"award-number":["74550801"]}]},{"name":"National Health Services in the counties of Copenhagen, Aarhus, Ringk\u00f8bing, Ribe, and Southern Jutland in Denmark"},{"DOI":"10.13039\/100007398","name":"Danish Council for Strategic Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007398","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Research Foundation for General Practice"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:p>The role of glucose-stimulated release of GLP-1 in the development of obesity and type 2 diabetes is unclear. We assessed GLP-1 response to oral glucose in a large study population of lean and obese men and women with normal and impaired glucose regulation. Circulating concentrations of glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with normal glucose tolerance (NGT) (n = 774), prediabetes (n = 525), or screen-detected type 2 diabetes (n = 163) who attended the Danish ADDITION-PRO study (n = 1,462). Compared with individuals with NGT, women with prediabetes or type 2 diabetes had 25% lower GLP-1 response to an OGTT, and both men and women with prediabetes or type 2 diabetes had 16\u201321% lower 120-min GLP-1 concentrations independent of age and obesity. Obese and overweight individuals had up to 20% reduced GLP-1 response to oral glucose compared with normal weight individuals independent of glucose tolerance status. Higher GLP-1 responses were associated with better insulin sensitivity and \u03b2-cell function, older age, and lesser degree of obesity. Our findings indicate that a reduction in GLP-1 response to oral glucose occurs prior to the development of type 2 diabetes and obesity, which can have consequences for early prevention strategies for diabetes.<\/jats:p>","DOI":"10.2337\/db14-1751","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T05:50:58Z","timestamp":1423806658000},"page":"2513-2525","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":301,"title":["GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study"],"prefix":"10.2337","volume":"64","author":[{"given":"Kristine","family":"F\u00e6rch","sequence":"first","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe S.","family":"Torekov","sequence":"additional","affiliation":[{"name":"NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Vistisen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna B.","family":"Johansen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"},{"name":"Danish Diabetes Academy, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Witte","sequence":"additional","affiliation":[{"name":"Section for General Practice, Department of Public Health, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jonsson","sequence":"additional","affiliation":[{"name":"NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluf","family":"Pedersen","sequence":"additional","affiliation":[{"name":"NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Hansen","sequence":"additional","affiliation":[{"name":"NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Lauritzen","sequence":"additional","affiliation":[{"name":"Section for General Practice, Department of Public Health, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelli","family":"Sandb\u00e6k","sequence":"additional","affiliation":[{"name":"Section for General Practice, Department of Public Health, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[{"name":"NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit E.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"key":"2022031212491313300_B1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031212491313300_B2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"2022031212491313300_B3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/eje.0.1350425","article-title":"Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)\u2014evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins","volume":"135","author":"Vaag","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"2022031212491313300_B4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia"},{"key":"2022031212491313300_B5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia"},{"key":"2022031212491313300_B6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.7150\/ijms.4128","article-title":"Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance","volume":"9","author":"Zhang","year":"2012","journal-title":"Int J Med Sci"},{"key":"2022031212491313300_B7","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes"},{"key":"2022031212491313300_B8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/EJE-13-0487","article-title":"Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT","volume":"169","author":"Alssema","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2022031212491313300_B9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00125-007-0899-2","article-title":"Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and\/or impaired glucose tolerance in the EUGENE2 study","volume":"51","author":"Laakso","year":"2008","journal-title":"Diabetologia"},{"key":"2022031212491313300_B10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.metabol.2003.11.011","article-title":"Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance","volume":"53","author":"Rask","year":"2004","journal-title":"Metabolism"},{"key":"2022031212491313300_B11","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031212491313300_B12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00125-008-0951-x","article-title":"Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action","volume":"51","author":"F\u00e6rch","year":"2008","journal-title":"Diabetologia"},{"key":"2022031212491313300_B13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.2010.184","article-title":"Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1","volume":"88","author":"Migoya","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2022031212491313300_B14","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gut.38.6.916","article-title":"Attenuated GLP-1 secretion in obesity: cause or consequence","volume":"38","author":"Ranganath","year":"1996","journal-title":"Gut"},{"key":"2022031212491313300_B15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2337\/db07-1124","article-title":"Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance","volume":"57","author":"Vollmer","year":"2008","journal-title":"Diabetes"},{"key":"2022031212491313300_B16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s00125-009-1443-3","article-title":"Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?","volume":"52","author":"F\u00e6rch","year":"2009","journal-title":"Diabetologia"},{"key":"2022031212491313300_B17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s00125-010-1673-4","article-title":"Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study","volume":"53","author":"F\u00e6rch","year":"2010","journal-title":"Diabetologia"},{"key":"2022031212491313300_B18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0016-5085(89)90758-0","article-title":"Influence of gender and menopause on gastric emptying and motility","volume":"96","author":"Hutson","year":"1989","journal-title":"Gastroenterology"},{"key":"2022031212491313300_B19","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.2337\/dc13-0592","article-title":"Impact of glucose tolerance status, sex, and body size on glucose absorption patterns during OGTTs","volume":"36","author":"F\u00e6rch","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031212491313300_B20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.genm.2009.02.002","article-title":"Gender differences in insulin resistance, body composition, and energy balance","volume":"6","author":"Geer","year":"2009","journal-title":"Gend Med"},{"key":"2022031212491313300_B21","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.ijo.0801420","article-title":"The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening","volume":"24","author":"Lauritzen","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031212491313300_B22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1186\/1471-2458-12-1078","article-title":"Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care","volume":"12","author":"Johansen","year":"2012","journal-title":"BMC Public Health"},{"key":"2022031212491313300_B23","first-page":"359","article-title":"Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours","volume":"24","author":"Holst","year":"1983","journal-title":"Diabetologia"},{"key":"2022031212491313300_B24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"\u00d8rskov","year":"1994","journal-title":"Diabetes"},{"key":"2022031212491313300_B25","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1210\/jc.2011-0266","article-title":"Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans","volume":"96","author":"Lindgren","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031212491313300_B26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0168-8227(99)00116-3","article-title":"Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures","volume":"47","author":"Gutt","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031212491313300_B27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1172\/JCI105534","article-title":"Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus","volume":"46","author":"Seltzer","year":"1967","journal-title":"J Clin Invest"},{"key":"2022031212491313300_B28","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1210\/jc.2013-3994","article-title":"GIP contributes to islet trihormonal abnormalities in type 2 diabetes","volume":"99","author":"Chia","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031212491313300_B29","doi-asserted-by":"crossref","first-page":"E550","DOI":"10.1152\/ajpendo.00326.2004","article-title":"Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP","volume":"290","author":"Theodorakis","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031212491313300_B30","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"key":"2022031212491313300_B31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2337\/dc13-1283","article-title":"GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance","volume":"37","author":"Matikainen","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031212491313300_B32","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00125-012-2484-6","article-title":"Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits","volume":"55","author":"Gjesing","year":"2012","journal-title":"Diabetologia"},{"key":"2022031212491313300_B33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1463-1326.2011.01388.x","article-title":"Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes","volume":"13","author":"Torekov","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031212491313300_B34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/dom.12240","article-title":"Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12\u2009weeks in patients with type 2 diabetes mellitus","volume":"16","author":"Torekov","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031212491313300_B35","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/db11-1701","article-title":"The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes","volume":"61","author":"Woerle","year":"2012","journal-title":"Diabetes"},{"key":"2022031212491313300_B36","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.2337\/db13-0140","article-title":"Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, \u03b2-cell function, and glucose metabolism in nondiabetic subjects","volume":"62","author":"Sathananthan","year":"2013","journal-title":"Diabetes"},{"key":"2022031212491313300_B37","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.1152\/ajpendo.00283.2013","article-title":"GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle","volume":"306","author":"Sj\u00f8berg","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031212491313300_B38","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jcem.86.8.7743","article-title":"Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031212491313300_B39","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1007\/s00125-011-2265-7","article-title":"Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1","volume":"54","author":"Torekov","year":"2011","journal-title":"Diabetologia"},{"key":"2022031212491313300_B40","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/sj.ijo.0801655","article-title":"The role of postprandial releases of insulin and incretin hormones in meal-induced satiety\u2014effect of obesity and weight reduction","volume":"25","author":"Verdich","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031212491313300_B41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00125-009-1596-0","article-title":"Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease","volume":"53","author":"Nathanson","year":"2010","journal-title":"Diabetologia"},{"key":"2022031212491313300_B42","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1210\/jc.2013-3809","article-title":"Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease","volume":"99","author":"Idorn","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031212491313300_B43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jdiacomp.2013.10.008","article-title":"Approaching pre-diabetes","volume":"28","author":"Perreault","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2022031212491313300_B44","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031212491313300_B45","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031212491313300_B46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jc.2010-2435","article-title":"Impaired regulation of the incretin effect in patients with type 2 diabetes","volume":"96","author":"Bagger","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031212491313300_B47","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/dom.12352","article-title":"Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies","volume":"16","author":"Bak","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031212491313300_B48","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s00125-011-2168-7","article-title":"Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs","volume":"54","author":"Hj\u00f8llund","year":"2011","journal-title":"Diabetologia"},{"key":"2022031212491313300_B49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00125-005-1705-7","article-title":"Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors","volume":"48","author":"Holst","year":"2005","journal-title":"Diabetologia"},{"key":"2022031212491313300_B50","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"2022031212491313300_B51","article-title":"Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss","author":"Iepsen","journal-title":"Int J Obes (Lond)"},{"key":"2022031212491313300_B52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1467-789X.2011.00860.x","article-title":"Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential","volume":"12","author":"Torekov","year":"2011","journal-title":"Obes Rev"},{"key":"2022031212491313300_B53","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/diabetes.diabetesjournals.org\/syndication\/doi\/10.2337\/db14-1751","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/64\/7\/2513\/580361\/db141751.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/64\/7\/2513\/580361\/db141751.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:45:01Z","timestamp":1667407501000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/64\/7\/2513\/19197\/GLP-1-Response-to-Oral-Glucose-Is-Reduced-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,2,12]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db14-1751","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]}}}